<DOC>
	<DOCNO>NCT00660075</DOCNO>
	<brief_summary>Sitagliptin potent selective inhibitor dipeptidyl peptidase IV ( DPP-4 ) , show reduce fast postprandial glucose level patient type 2 diabetes mainly incretin hormone-mediated improvement islet function . Although clinical study date indicate fast lipid level minimally affect DPP-4 inhibitor treatment , animal study suggest DPP-4 inhibition reduce intestinal triglyceride ( TG ) absorption apolipoprotein production increase chylomicron catabolism . Therefore , present study design examine effect sitagliptin postprandial lipemia patient type 2 diabetes . A possible reduction postprandial atherogenic triglyceride-rich lipoprotein ( TRL ) level sitagliptin would add therapeutic utility DPP-4 inhibitor suggest potential reduce cardiovascular risk patient type 2 diabetes .</brief_summary>
	<brief_title>Effects Sitagliptin Postprandial Lipemia Men With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes define American Diabetes Association ; Nonsmoker ; Body mass index 25.0 40.0 kg/m2 ; Baseline HbA1c 6.5 8.5 % ; Baseline fast plasma glucose &lt; 15.0 mmol/L ; Plasma triglyceride level 1.5 8.0 mmol/L ( 135 710 mg/dl ) week 4 ; Patients receive stable dos metformin least 3 month randomization ; Subjects must willing give write informed consent able adhere dose schedule , visit schedule phone followup assessment ; Patients otherwise generally healthy , without elevation hepatic transaminase abnormal renal function coagulation ; Patients normal TSH screening . Patients extreme dyslipidemias , familial hypercholesterolemia exclude ; Patients type 1 diabetes , secondary form diabetes acute metabolic diabetic complication exclude ; Patients receive treated insulin thiazolidinedione within past 6 month exclude ; Subjects exclude cardiovascular disease ( CVD ) ( coronary heart disease , cerebrovascular disease peripheral arterial disease ) take medication know affect lipoprotein metabolism ( e.g . steroid , beta blocker , thiazide diuretic , lipid lower agent , significant alcohol intake etc . ) ; Subjects situation condition , opinion investigator , may interfere optimal participation study ; Individuals history mental instability , drug alcohol abuse individual treat treat severe psychiatric illness , opinion investigator , may interfere optimal participation study ; History alcohol drug abuse within past 2 year . Patients must take alcohol study ; Disorders hematologic , digestive , central nervous system , include cerebrovascular disease degenerative disease , would limit study evaluation participation ; Known impairment renal function ( serum creatinine level &gt; 1.7 mg/dL men ) , dysproteinemia , nephrotic syndrome , renal disease ( 24hour urinary protein ≥3 ± 1 g ) ; Active chronic hepatobiliary hepatic disease . In addition , patient AST ALT &gt; 2 x upper limit laboratory reference range exclude ; Subjects coagulopathy ( prothrombin time [ PT ] partial thromboplastin time [ PTT ] Visit 1 &gt; 1.5 time control ; Patients know tested positive human immunodeficiency virus ( HIV ) ; Patients currently enrol another clinical study ; Patients use investigational drug within 30 day first clinic visit ; Congestive heart failure NYHA Class III IV . Uncontrolled cardiac arrhythmia within 3 month study entry ; Uncontrolled diabetes mellitus ( HbA1c &gt; 8.5 % ) endocrine metabolic disease know influence serum lipid lipoprotein . Clinically euthyroid subject replacement dose thyroid hormone eligible enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Postprandial</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>